Overview

5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

Status:
NOT_YET_RECRUITING

Trial end date:
2030-12-30

Target enrollment:

Participant gender:

Summary

5-fluorouracil (5-FU) is a standard of care in frail/elderly patients with an unresectable colorectal adenocarcinoma (CRC) in first-line setting. Panitumumab plus Sotorasib are promising in advanced line in KRAS G12C mutated CRC. In this study, We assess the safety and efficacy of 5FU combination with Panitumumab and Sotorasib as first-line treatment in frail/elderly patients with unresectable KRAS G12C mutated CRC

Phase:

PHASE2

Details

Lead Sponsor:

Federation Francophone de Cancerologie Digestive

Collaborators:

Arbeitsgemeinschaft fur Internistische Onkologie
Northwest Oncology Cooperative Group(GONO)
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Treatments:

sotorasib